Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies (NASDAQ: CLGN) operates at the intersection of plant biotechnology and regenerative medicine, creating news flow that spans bioprinting research breakthroughs, clinical development milestones, and commercial partnership announcements. As a specialty biotechnology company producing recombinant human collagen from genetically engineered plants, CollPlant generates coverage distinct from traditional pharmaceutical or medical device companies.
News coverage for CollPlant typically includes research collaboration announcements with academic institutions and medical centers developing 3D bioprinting applications. The company's partnerships with organizations such as Mayo Clinic and Technion-Israel Institute of Technology produce updates on bioprinting advancements and preclinical study results. These announcements provide insight into the trajectory of tissue engineering applications using the company's rhCollagen technology.
Commercial developments form another significant news category, including distribution agreement expansions for the VergenixSTR product line across European and Asian markets. Patent grants and regulatory approvals for collagen-based formulations mark intellectual property milestones that affect the company's competitive position in the biomaterials sector.
As a dual-listed company on NASDAQ and the Tel Aviv Stock Exchange, CollPlant releases quarterly financial results and corporate updates that detail research progress, commercial traction, and capital position. These announcements help track the company's progress toward broader commercialization of its plant-derived collagen platform.
Bookmark this page to follow CollPlant's bioprinting research developments, tissue repair product expansions, and partnership announcements as the company advances its regenerative medicine technology.
CollPlant Biotechnologies (Nasdaq: CLGN) reported its Q1 2024 financial results and provided a corporate update. The company initiated a new large-animal study for its 3D-bioprinted breast implants in December 2023, expected to conclude in June 2024. Q1 2024 GAAP revenue was $98,000, a decrease from $433,000 in Q1 2023. Costs of revenue increased to $545,000 from $325,000, resulting in a gross loss of $447,000 compared to a gross profit of $108,000 in Q1 2023. Net loss widened to $4.2 million from $3.7 million. The company also highlighted advancements in its Environmental, Social, and Governance (ESG) initiatives and recent patent approvals in the U.S., Brazil, Israel, and Australia. Cash and cash equivalents as of March 31, 2024, stood at $23.2 million.
CollPlant Biotechnologies (Nasdaq: CLGN) announced the release of its financial results for the first quarter of 2024 on May 29, 2024, before U.S. market opening. The company will host a conference call and webcast the same day at 10:00 a.m. EDT to discuss these results and provide corporate updates.
U.S. investors can dial 1-877-407-9716, international investors can call 1-201-493-6779, and Israeli investors can dial 1-809-406-247 using Conference ID 13745964. Participants can avoid long wait times by using the Call me™ feature available 15 minutes prior to the call.
A live listen-only webcast will be available, with a replay accessible on the company's website for a period. Questions for management can be submitted via email to Dan Ferry at LifeSci Advisors up to 24 hours before the event.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
